Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;79(3):1297-1305.
doi: 10.3233/JAD-200944.

Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes

Affiliations

Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes

Ira Driscoll et al. J Alzheimers Dis. 2021.

Erratum in

Abstract

Background: Identification of new genetic variants that modify Alzheimer's disease (AD) risk will elucidate novel targets for curbing the disease progression or delaying symptom onset.

Objective: To examine whether the functionally advantageous KLOTHO gene KL-VS variant attenuates age-related alteration in cerebrospinal fluid (CSF) biomarkers or cognitive function in middle-aged and older adults enriched for AD risk.

Methods: Sample included non-demented adults (N = 225, mean age = 63±8, 68% women) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center who were genotyped for KL-VS, underwent CSF sampling and had neuropsychological testing data available proximal to CSF draw. Covariate-adjusted multivariate regression examined relationships between age group (Younger versus Older; mean split at 63 years), AD biomarkers, and neuropsychological performance tapping memory and executive function, and whether these relationships differed between KL-VS non-carriers (KL-VSNC) and heterozygote (KL-VSHET).

Results: In the pooled analyses, older age was associated with higher levels of total tau (tTau), phosphorylated tau (pTau), and their respective ratios to amyloid-β (Aβ)42 (ps ≤ 0.002), and with poorer performance on neuropsychological tests (ps ≤ 0.001). In the stratified analyses, KL-VSNC exhibited this age-related pattern of associations with CSF biomarkers (all ps ≤ 0.001), and memory and executive function (ps ≤ 0.003), which were attenuated in KL-VSHET (ps ≥ 0.14).

Conclusion: Worse memory and executive function, and higher tau burden with age were attenuated in carriers of a functionally advantageous KLOTHO variant. KL-VS heterozygosity seems to be protective against age-related cognitive and biomolecular alterations that confer risk for AD.

Keywords: Alzheimer’s disease; biomarkers; cerebrospinal fluid; executive function; memory.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Age differentially associates with CSF tau measures as a function of KL-VS status.
Bar graphs depicting group differences (M(SE)) in tau between Younger (black) and Older (white) individuals. Among KL-VSNC, Older age was associated with worse levels of A) total tau (tTau), B) phosphorylated tau (pTau), and their respective ratios to Aβ42 (C & D). This age-related pattern of associations with CSF tau biomarkers was abated in KL-VSHET. Abbreviations: M=mean; SE=standard error; Aβ42 = β-amyloid42; tTau = total tau; pTau = phosphorylated tau; KL-VSNC = KL-VS non-carriers; KL-VSHET = KL-VS heterozygotes.
Figure 2.
Figure 2.. Age differentially associates with measures of episodic memory and executive function as a function of KL-VS status.
Bar graphs depicting group differences (M(SE)) in cognition between Younger (black) and Older (white) individuals. KL-VSNC exhibited age-related deficits in memory (A & B) and executive function (C & D), which were attenuated in KL-VSHET. Abbreviations: M=mean; SE=standard error; RAVLT = Rey Auditory Verbal Learning Test (total trials); TMT = Trail Making Test (time in seconds); KL-VSNC = KL-VS non-carriers; KL-VSHET = KL-VS heterozygotes.

References

    1. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019;15:565–581. - PubMed
    1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14:367–429.
    1. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016;18:421. - PMC - PubMed
    1. Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging 2019;83:124–129. - PMC - PubMed
    1. Gallagher M, Okonkwo OC, Resnick SM, Jagust WJ, Benzinger TLS, Rapp PR. What are the threats to successful brain and cognitive aging? Neurobiol Aging 2019;83:130–134. - PMC - PubMed

Publication types

LinkOut - more resources